Partnering & Licensing

Exicure is using its proprietary SNA technology platform to build a broad pipeline of products for a range of diseases with unmet medical need. Exicure's strategy is to maximize the potential of its Spherical Nucleic Acid (SNA) technology platform through in-house development, collaborations and licensing.

Exicure may also establish platform partnerships with pharmaceutical companies across multiple indications or within specific therapeutic areas.

For more information regarding Exicure's partnering strategy, please contact Business Development department, licensing at exicuretx dot com